Aegerion Pharmaceuticals, Inc. 4
4 · Aegerion Pharmaceuticals, Inc. · Filed Jul 29, 2011
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2011-07-29$14.61/sh−5,069$74,052→ 2,629,377 total(indirect: see footnote)
Footnotes (1)
- [F1]These securities are indirectly beneficially owned in the following capacities; as General Partner of AHLS III GP, which in turn is the General Partner of Advent Healthcare & Life Sciences III Limited Partnership and Advent Healthcare & Life Science III A Limited Partnership.